Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Elzbieta Kaszuba, Lund University
ClinicalTrials.gov Identifier:
NCT01801722
First received: February 25, 2013
Last updated: February 28, 2013
Last verified: February 2013
  Purpose

The aim of the present study was to evaluate if the analysis of NT-proBNP might be used as an initial step for the diagnosis of chronic heart failure in patients with COPD in primary health care, and to select patients for a further examination by echocardiography.


Condition
Chronic Obstructive Pulmonary Disease
Chronic Heart Failure

Study Type: Observational
Study Design: Time Perspective: Cross-Sectional
Official Title: Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.

Resource links provided by NLM:


Further study details as provided by Lund University:

Primary Outcome Measures:
  • Percentage of patients with elevated NT-proBNP. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    NT-proBNP has taken only once in each patient without follow up follow up. Three months was a period when we collected data from all participants.


Secondary Outcome Measures:
  • Percentage of patients with abnormal left ventricular function assessed by echocardiography. Association between elevated NT-proBNP and symptoms, signs and electrocardiography. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Echocardiography was performed once in each referred patient. Three months was a period of data collection.


Enrollment: 75
Study Start Date: April 2008
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
NT-proBNP,ejection fraction ,COPD stage.
The group comprised 25 women (47%) and 28 men (53%). The mean age was 75.4 years (SD 7.9), 76.3 (SD 7.6) for men and 74.4 (SD 8.2) for women.

Detailed Description:

Patients with a confirmed diagnosis of COPD were examined regarding chronic heart failure.

  1. An interview regarding symptoms: breathlessness, orthopnoea, night cough, nocturia, walking distance.
  2. Physical examination: weight and height, heart and lung auscultation, blood pressure measurement after 5 minutes' rest in the sitting position and the presence of peripheral oedema.
  3. Electrocardiography.
  4. Natriuretic peptide- NT-proBNP (Immulite 2500, Siemens Healthcare Diagnostics AB Sweden).
  5. Patients with the NT-proBNP level of > 1200 pg/ml were referred for echocardiography to assess left ventricular function.
  Eligibility

Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients aged 65 years and older with a registered diagnosis of COPD.

Criteria

Inclusion Criteria:

  • Patients aged 65 years and older with the following diagnosis codes according to International Statistical Classification of Diseases and Related Health Problems - Tenth Revision:J44 (COPD) and J41, J42 (chronic bronchitis) registered during the period 1 January 2008-16 April 2008 according to the electronic patient record.

Exclusion Criteria:

  • Impaired cognitive function and/or anticipated difficulties in carrying out spirometry due to immobility,
  • psychiatric disorders or terminal illness.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01801722

Locations
Sweden
Primary health care center.
Olofström, Blekinge, Sweden, 29332
Sponsors and Collaborators
Lund University
Investigators
Principal Investigator: Elzbieta Kaszuba, PhD student Lund University
  More Information

No publications provided

Responsible Party: Elzbieta Kaszuba, PhD student, Lund University
ClinicalTrials.gov Identifier: NCT01801722     History of Changes
Other Study ID Numbers: 502008, DN50/2008
Study First Received: February 25, 2013
Last Updated: February 28, 2013
Health Authority: Sweden: Regional Ethical Review Board

Additional relevant MeSH terms:
Heart Failure
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Heart Diseases
Cardiovascular Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on April 17, 2014